Seddik Mimouna, Meliez Hugues, Seguy David, Viget Nathalie, Cortot Antoine, Colombel Jean Frederic
Department of Gastroenterology, CHRU Lille, rue Michel Polonovsky, Lille, France.
Inflamm Bowel Dis. 2004 Jul;10(4):436-7. doi: 10.1097/00054725-200407000-00017.
Anti-TNFalpha therapy is an effective treatment of Crohn's disease. There is an increased risk of infection, including atypical infection associated in infliximab treated patients. We report a case of a young man who developed Pneumocystisjiroveci pneumonia shortly after starting therapy with infliximab. Thus, although rare, prophylaxis against Pneumocystis jiroveci pneumonia might be considered when starting a treatment with infliximab, especially in patients receiving concomitant immunosuppressive agents.
抗TNFα疗法是克罗恩病的一种有效治疗方法。使用英夫利昔单抗治疗的患者发生感染的风险增加，包括非典型感染。我们报告了一例年轻男性在开始使用英夫利昔单抗治疗后不久发生耶氏肺孢子菌肺炎的病例。因此，虽然罕见，但在开始使用英夫利昔单抗治疗时，尤其是对于正在接受免疫抑制剂治疗的患者，可能需要考虑预防耶氏肺孢子菌肺炎。
